SHTDY OTC
Sinopharm Group Co. Ltd.
1W: -0.8%
1M: -3.9%
3M: -14.9%
YTD: -25.9%
1Y: -20.7%
3Y: -30.0%
5Y: -17.5%
$9.35
+0.02 (+0.21%)
Weekly Expected Move ±2.6%
$9
$9
$9
$10
$10
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$559.5B
-4.3% ▼
5Y CAGR: +4.2%
Gross Profit
$40.1B
-9.4% ▼
5Y CAGR: -0.1%
Operating Income
$16.2B
+0.1% ▲
5Y CAGR: -1.8%
Net Income
$7.0B
-1.3% ▼
5Y CAGR: -0.6%
EPS (Diluted)
$11.10
-1.8% ▼
5Y CAGR: -0.8%
EBITDA
$20.4B
+1.0% ▲
5Y CAGR: -2.1%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $521.1B | $552.1B | $596.6B | $584.5B | $559.5B |
| YoY Growth | +14.2% | +6.0% | +8.0% | -2.0% | -4.3% |
| Cost of Revenue | $477.0B | $504.7B | $548.1B | $540.3B | $519.4B |
| Gross Profit | $44.1B | $47.4B | $48.5B | $44.3B | $40.1B |
| Gross Margin | 8.5% | 8.6% | 8.1% | 7.6% | 7.2% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $23.2B | $24.9B | $26.1B | $25.6B | $23.9B |
| Operating Expenses | $24.3B | $26.8B | $28.3B | $28.1B | $23.9B |
| Operating Income | $19.7B | $20.6B | $20.2B | $16.2B | $16.2B |
| Operating Margin | 3.8% | 3.7% | 3.4% | 2.8% | 2.9% |
| Interest Expense | $3.8B | $3.5B | $3.0B | $2.7B | $2.4B |
| Income Before Tax | $17.0B | $18.6B | $19.5B | $14.0B | $14.4B |
| Tax Expense | $3.9B | $4.2B | $4.5B | $3.6B | $3.9B |
| Net Income | $7.8B | $8.5B | $9.1B | $7.0B | $7.0B |
| Net Margin | 1.5% | 1.5% | 1.5% | 1.2% | 1.2% |
| EPS (Diluted) | $12.45 | $13.65 | $14.50 | $11.30 | $11.10 |
| EBITDA | $24.7B | $26.2B | $26.9B | $20.2B | $20.4B |
| Shares Outstanding | 622M | 624M | 624M | 624M | 624M |